Jason Harris

Senior Editor, OncLive®
Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for OncologyLive® and managing editor for Oncology Fellows and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: jharris@onclive.com


Articles

Lessons Learned May Hold the Key for Improving Outcomes in Fibrolamellar Carcinoma

October 21st 2021

Fibrolamellar carcinoma is an extremely rare form of liver cancer that affects approximately 1 in 5 million Americans. However, because the disease appears so infrequently, it may be underdiagnosed.

Find Joy in the Job

October 9th 2021

Michael L. Grossbard, MD, discusses what to look for when choosing a mentor and a fellowship program.

NICE Recommends Atezolizumab for Advanced Urothelial Cancer

September 30th 2021

The National Institute for Clinical Excellence has issued final guidance supporting the use of atezolizumab for patients with treatment-naïve, PD–L1–positive locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin.

Investigators Seek to Preserve Fertility in Ovarian Malignant Germ Cell Tumors

September 28th 2021

Germ cell tumors of the ovary are aggressive tumors derived from the primitive germ cells of the embryonic gonad and appear most often in young women or adolescent girls.

Optellum, Johnson & Johnson Launch Strategic Collaboration in Lung Cancer

September 26th 2021

Optellum and the Lung Cancer Initiative at Johnson & Johnson plan to use Optellum’s artificial intelligence-based decision support software in an effort to increase lung cancer survival rates via disease prevention and early intervention.

Regorafenib Confers No PFS Benefit in Advanced Chordoma

September 22nd 2021

Regorafenib did not show a benefit with progression-free survival in patients with advanced or metastatic chordoma.

Sitravatinib/Nivolumab Combo Results in Durable Response in Advanced NSCLC Following Checkpoint Inhibitors, Chemotherapy

September 21st 2021

Sitravatinib, a spectrum-selective TKI targeting TAM receptors and VEGFR2, administered in combination with nivolumab induced durable response and robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

ctDNA a Viable Surrogate for OS in Previously Treated Metastatic Uveal Melanoma

September 19th 2021

Circulating tumor DNA was a better predictor for survival than RECIST 1.1 for patients with previously treated, HLA-A*02:01-positive metastatic uveal melanoma assigned to tebentafusp.

Daily Poziotinib Shows Promise in Untreated HER2 Exon 20–Mutant NSCLC

September 18th 2021

Poziotinib, administered once daily at 16 mg, induced a median tumor reduction of 35% in patients with treatment-naïve non–small cell lung cancer harboring HER2 exon 20 mutations, according to findings from cohort 4 of the ongoing phase 2 ZENITH20 trial.

Sintilimab Improves OS in Advanced ESCC, Gastric/GEJ Cancer

September 17th 2021

Findings from a pair of studies presented at the 2021 European Society for Medical Oncology Annual Meeting showed that adding sintilimab to chemotherapy significantly improved overall survival compared with chemotherapy alone in patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma and those with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.

MRgFUS Improved Sexual Function, Urinary Continence in Men with Intermediate-Risk Prostate Cancer

September 13th 2021

Magnetic resonance-guided focused ultrasound focal therapy delivered to the index lesion produced better outcomes for men with intermediate-risk prostate cancer compared with radical prostatectomy or radiation therapy.

TAR-200/Cetrelimab Under Investigation in Muscle-Invasive Bladder Cancer

September 11th 2021

TAR-200 plus cetrelimab may offer a superior treatment option for patients with muscle-invasive bladder cancer, and to answer this questions, investigators have initiated the randomized, phase 3 SunRISe-2 trial.

BMI Is a Significant Predictor for Survival in mCRPC

September 10th 2021

Obese men with metastatic castration-resistant prostate cancer have better disease-specific and overall survival than overweight or normal weight patients.

Gynecologic Oncology Pioneer Franco Muggia Dies at 85

September 10th 2021

Franco Muggia, MD, a fixture at NYU Langone’s Perlmutter Cancer Center and a leader in the study and treatment of patients with gynecologic cancers, died on September 8, 2021. He was 85 years old.

Controlling Infections Could Be Key to Improving Survival in CLL

September 9th 2021

Patients with chronic lymphocytic leukemia are at an increased risk for infection whether they are in the premalignant state of monoclonal B lymphocytosis, during active surveillance for those are treatment naïve, or are on active treatment.

TDM-1/Osimertinib Combo Has Limited Efficacy for Resistant EGFR+ NSCLC

September 8th 2021

The combination of ado-trastuzumab emtansine and osimertinib demonstrated minimal antitumor effects on patients with EGFR-mutated non–small cell lung cancer, according to interim data of the phase 2 TRAEMOS trial.

SIRT With Y90 Plus Chemotherapy Extends Survival for Intrahepatic Cholangiocarcinoma

September 4th 2021

The addition of selective internal radiation therapy with Y90 resin microspheres to gemcitabine/cisplatin resulted in a median overall survival of 21.6 months for patients with inoperable intrahepatic cholangiocarcinoma, according to prospective phase 2 data.

Checkpoint Inhibitors, Electrical Fields Provide New Options for Mesothelioma

August 31st 2021

Despite an outsized reputation fueled by late-night commercials from personal injury lawyers, mesothelioma is a rare disease with approximately 3000 new diagnoses every year in the United States.

NICE Recommends Abemaciclib for HR+/HER2– Advanced Breast Cancer

August 12th 2021

The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance supporting the use of abemaciclib in the treatment of adult patients with metastatic hormone receptor–positive/HER2-negative breast cancer.

Smarter Screening, Risk Assessments Are Key to Eliminating Racial Disparities in Breast Cancer Outcomes

August 9th 2021

“Smarter screening” and a better understanding of the breast cancers women of color are more likely to develop are all crucial to helping these patients survive this disease at the same rates as their White counterparts.